- Home
- ACH vs IPSC Comparison
ACH vs IPSC Comparison
Compare ACH & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACH | IPSC |
|---|---|---|
| Founded | 1882 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.3M | 189.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACH | IPSC |
|---|---|---|
| Price | $2.36 | $2.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.38 | ★ $3.50 |
| AVG Volume (30 Days) | 738.1K | ★ 972.0K |
| Earning Date | 01-01-0001 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $1.84 | $0.34 |
| 52 Week High | $2.80 | $2.97 |
Technical Indicators
Market Signals| Indicator | ACH | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 52.38 |
| Support Level | $2.20 | $0.49 |
| Resistance Level | $2.48 | $2.71 |
| Average True Range (ATR) | 0.16 | 0.25 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 43.96 | 30.06 |
Price Performance
Historical ComparisonAbout ACH Accendra Health Inc.
Accendra Health Inc is a world-wide healthcare solutions company providing essential products, services and technology solutions that support care delivery in hospitals, health systems and research centers around the world.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.